<DOC>
	<DOCNO>NCT02096341</DOCNO>
	<brief_summary>To investigate dosage RRx-001 subcutaneous route .</brief_summary>
	<brief_title>A Phase 1 Pilot Study Subcutaneous ( s.c. ) Route Facilitate Administration RRx-001</brief_title>
	<detailed_description>This phase I , open-label , dose-escalation study RRx-001 . Subjects receive RRx-001 administer subcutaneous injection twice weekly least 8 week . At least three subject must complete 2 week treatment RRx-001 dose level , escalation next high RRx-001 dose level ; 2 doses—16 27 mg/m2— test . The purpose study extend dosage option RRx-001 since faster subcutaneous ( SC ) administration may increase convenience versus traditional IV method . The study also also measure mean concentration RRx-001 metabolite blood ( pharmacokinetics ; PK ) versus IV formulation .</detailed_description>
	<criteria>At least 18 year old . ECOG ( performance ) status 0 , 1 2 . Histologically cytologically confirm primary metastatic advance solid tumor lymphoma . Subjects curative treatment option eligible protocol . No active ongoing cancer treatment ( except prostate cancer subject receive luteinizing hormonereleasing hormone ( LHRH ) agonists antiandrogens ; Flutamide , Dutasteride , Finasteride ) . Adequate organ bone marrow function . Male female subject childbearing potential must agree use contraception . Pregnant breastfeeding . Use anticoagulant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>